Institute Of Biomedical Stock Net Income
| MRES Stock | USD 0 0.0003 13.64% |
As of the 13th of February 2026, Institute retains the Downside Deviation of 21.65, market risk adjusted performance of (0.12), and Risk Adjusted Performance of 0.0299. Concerning fundamental indicators, the technical analysis model lets you check existing technical drivers of Institute of Biomedical, as well as the relationship between them. Please check out Institute of Biomedical information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Institute is priced fairly, providing market reflects its last-minute price of 0.0025 per share. As Institute of Biomedical appears to be a penny stock we also urge to confirm its total risk alpha numbers.
Institute's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Institute's valuation are provided below:Institute of Biomedical does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Institute |
Institute 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Institute's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Institute.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Institute on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Institute of Biomedical or generate 0.0% return on investment in Institute over 90 days. Institute is related to or competes with Rocket Pharmaceuticals, Aura Biosciences, Annexon, Solid Biosciences, Larimar Therapeutics, Altimmune, and Autolus Therapeutics. Institute of Biomedical Research Corp. provides biomedical research and analytical services in Montenegro and internatio... More
Institute Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Institute's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Institute of Biomedical upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 21.65 | |||
| Information Ratio | 0.0214 | |||
| Maximum Drawdown | 111.97 | |||
| Value At Risk | (28.21) | |||
| Potential Upside | 47.22 |
Institute Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Institute's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Institute's standard deviation. In reality, there are many statistical measures that can use Institute historical prices to predict the future Institute's volatility.| Risk Adjusted Performance | 0.0299 | |||
| Jensen Alpha | 0.8515 | |||
| Total Risk Alpha | (1.42) | |||
| Sortino Ratio | 0.0224 | |||
| Treynor Ratio | (0.13) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Institute's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Institute February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0299 | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 14.44 | |||
| Semi Deviation | 15.79 | |||
| Downside Deviation | 21.65 | |||
| Coefficient Of Variation | 4007.17 | |||
| Standard Deviation | 22.68 | |||
| Variance | 514.54 | |||
| Information Ratio | 0.0214 | |||
| Jensen Alpha | 0.8515 | |||
| Total Risk Alpha | (1.42) | |||
| Sortino Ratio | 0.0224 | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 111.97 | |||
| Value At Risk | (28.21) | |||
| Potential Upside | 47.22 | |||
| Downside Variance | 468.51 | |||
| Semi Variance | 249.29 | |||
| Expected Short fall | (24.39) | |||
| Skewness | 1.24 | |||
| Kurtosis | 3.17 |
Institute of Biomedical Backtested Returns
Institute appears to be out of control, given 3 months investment horizon. Institute of Biomedical holds Efficiency (Sharpe) Ratio of 0.0374, which attests that the entity had a 0.0374 % return per unit of risk over the last 3 months. By evaluating Institute's technical indicators, you can evaluate if the expected return of 0.87% is justified by implied risk. Please utilize Institute's Risk Adjusted Performance of 0.0299, downside deviation of 21.65, and Market Risk Adjusted Performance of (0.12) to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Institute holds a performance score of 2. The company retains a Market Volatility (i.e., Beta) of -4.18, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Institute are expected to decrease by larger amounts. On the other hand, during market turmoil, Institute is expected to outperform it. Please check Institute's potential upside, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether Institute's current trending patterns will revert.
Auto-correlation | 0.35 |
Below average predictability
Institute of Biomedical has below average predictability. Overlapping area represents the amount of predictability between Institute time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Institute of Biomedical price movement. The serial correlation of 0.35 indicates that nearly 35.0% of current Institute price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.35 | |
| Spearman Rank Test | 0.2 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Institute of Biomedical reported net income of 564.67 K. This is 99.83% lower than that of the Healthcare sector and 99.19% lower than that of the Biotechnology industry. The net income for all United States stocks is 99.9% higher than that of the company.
Institute Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Institute's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Institute could also be used in its relative valuation, which is a method of valuing Institute by comparing valuation metrics of similar companies.Institute is currently under evaluation in net income category among its peers.
Institute Fundamentals
| Current Valuation | 198.84 K | |||
| Shares Outstanding | 66.28 M | |||
| Price To Book | 0.69 X | |||
| Revenue | 1.41 M | |||
| Net Income | 564.67 K | |||
| Cash Flow From Operations | 2.06 M | |||
| Beta | 1.71 | |||
| Market Capitalization | 639.61 K | |||
| Total Asset | 5.28 M | |||
| Retained Earnings | (55.58 M) | |||
| Current Asset | 2.56 M | |||
| Current Liabilities | 3.8 M | |||
| Z Score | -14.0 | |||
| Net Asset | 5.28 M |
About Institute Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Institute of Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Institute using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Institute of Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Institute Pink Sheet Analysis
When running Institute's price analysis, check to measure Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Institute is operating at the current time. Most of Institute's value examination focuses on studying past and present price action to predict the probability of Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Institute's price. Additionally, you may evaluate how the addition of Institute to your portfolios can decrease your overall portfolio volatility.